文献速递妇科生殖医学

卵巢肿瘤保留生育功能手术及化疗后的卵巢功能、生育力与绝经发生情况

Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms.
PubMed 文献 · Gynecol Oncol · 2018-12-18

该研究纳入1980至2014年诊断为上皮性或非上皮性浸润性卵巢肿瘤、接受保留生育功能手术(±化疗)的548例绝经前患者,中位随访15.9年。非上皮性肿瘤患者中,化疗暴露与治疗期间及治疗后闭经风险升高、自然绝经年龄提前相关;上皮性肿瘤患者中未显示化疗与生育力下降相关。总体57%尝试妊娠,受孕率89%。

要点

  • 非上皮性卵巢肿瘤患者化疗暴露与治疗期间闭经风险升高相关(aOR 27,95%CI 12-61)。
  • 非上皮性卵巢肿瘤患者化疗暴露与治疗后闭经风险升高相关(aOR 5.42,95%CI 1-24)。
  • 非上皮性卵巢肿瘤患者化疗暴露与自然绝经年龄提前相关(校正β -5.52,95%CI -10.53至-0.52)。

核心结论

  • 非上皮性卵巢肿瘤患者化疗暴露与治疗期间闭经、治疗后闭经风险升高及自然绝经年龄提前相关;上皮性卵巢肿瘤患者化疗暴露与研究各项结局均无关联。
  • 接受保留生育功能手术的患者受孕率较高、早发性卵巢功能不全率较低;但在治疗前咨询中应讨论该方案在年轻人群中的风险。

研究设计与样本

  • 研究纳入1980年至2014年诊断的548例患者,其中上皮性卵巢肿瘤组198例、非上皮性卵巢肿瘤组350例,44%接受化疗,中位随访15.9年。
  • 纳入标准为诊断为上皮性或非上皮性浸润性卵巢肿瘤、绝经前、接受保留生育功能手术±化疗、有组织病理学确认及充分随访。
  • 采用逻辑回归和线性回归分析比较各组结局。

主要发现

  • 非上皮性卵巢肿瘤患者中,化疗暴露与治疗期间闭经风险升高相关(校正OR 27,95%CI 12至61,P<.0001)。
  • 非上皮性卵巢肿瘤患者中,化疗暴露与治疗后闭经风险升高相关(校正OR 5.42,95%CI 1至24,P=.0256)。
  • 非上皮性卵巢肿瘤患者中,化疗暴露与自然绝经年龄提前相关(校正β -5.52,95%CI -10.53至-0.52,P=.0313)。
  • 总体57%的患者尝试妊娠,受孕率为89%。
  • 上皮性卵巢肿瘤患者中,未证实化疗暴露与生育力下降相关(校正OR 3.05,95%CI 0.72至12.88,P=.1298)。

临床怎么用

  • 作者认为,在治疗前咨询中应讨论保留生育功能方案在年轻人群中的风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of chemotherapy exposure (CE) on ovarian function in young women with ovarian neoplasms undergoing fertility-sparing treatment (FST) remains unclear. We investigated whether CE is correlated with the outcomes (1) during-treatment and (2) post-treatment amenorrhea, (3) conception rate, (4) pregnancy outcome, and (5) spontaneous menopausal age. PATIENTS AND METHODS: Eligibility criteria were patients with a diagnosis of epithelial (EOC) or nonepithelial (no-EOC) invasive ovarian neoplasm, premenopausal age, undergoing FST ± CE, histopathology confirmation, and adequate follow-up. The groups' outcomes were compared by logistic and linear regression analysis. RESULTS: A total of 548 patients diagnosed during 1980 and 2014 were included, 198 in the EOC group and 350 in the no-EOC group, and 44% received chemotherapy, with a median follow-up of 15.9 years. In no-EOC patients, CE conferred a higher risk for Outcomes 1 (adjusted OR [aOR] 27; 95% CI 12 to 61; P < .0001) and 2 (aOR 5.42; 95% CI 1 to 24; P = .0256) and was associated with a younger menopausal age (adjusted β -5.52; 95% CI -10.53 to -0.52; P = .0313). Overall, 57% of patients attempted pregnancy, with a conception rate of 89%. In EOC patients, no association between CE and a decreased fertility was demonstrated (aOR, 3.05; 95% CI 0.72 to 12.88; P = .1298). CONCLUSIONS: CE in no-EOC was associated with an increased risk of during-treatment amenorrhea, post-treatment amenorrhea, and earlier spontaneous menopausal age; CE in EOC was not associated with any item at study. Patients undergoing FST had reassuringly high conception rates and low premature ovarian failure rates; however, in pretreatment counseling, the risks of this approach in such young population should be discussed.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ceppi L, Galli F, Lamanna M, et al. Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms. Gynecol Oncol. 2018. PMID: 30578004. doi:10.1016/j.ygyno.2018.11.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。